GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
- Published In:
- Expert opinion on drug metabolism & toxicology, 9(1), 17-29 (2013)
- Authors:
- Jespersen, Maria J, Knop, Filip K(9), Christensen, Mikkel
- Database ID:
- RPEP-02202
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02202APA
Jespersen, Maria J; Knop, Filip K; Christensen, Mikkel. (2013). GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.. Expert opinion on drug metabolism & toxicology, 9(1), 17-29. https://doi.org/10.1517/17425255.2013.731394
MLA
Jespersen, Maria J, et al. "GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.." Expert opinion on drug metabolism & toxicology, 2013. https://doi.org/10.1517/17425255.2013.731394
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxi..." RPEP-02202. Retrieved from https://rethinkpeptides.com/research/jespersen-2013-glp1-agonists-for-type
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.